Covid-19 stock

Discussion in 'Ask any question!' started by Weston Gross, Jul 17, 2020.

  1. Rick Williams

    Rick Williams New Member

    Joined:
    Sep 4, 2020
    Messages:
    1
    Likes Received:
    0
    Ruconest = corona aspirin

    The coronavirus is here to stay and vaccines will likely be working as the flu shot meaning many people getting sick each year. The symptoms are worse then those form the flu so next to a corona shot we need a new aspirin.

    I came to this conclusion by the following news: Pharming announces the publication of data from a compassionate use programme of RUCONEST® in COVID-19 patients in a peer-reviewed journal Leiden, The Netherlands, 17 August 2020: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) today announces the publication of data in the peer-reviewed journal, Frontiers in Immunology, from a compassionate use programme of five patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalised with related severe pneumonia that were treated with RUCONEST® (recombinant human C1 inhibitor, conestat alfa) at the University Hospital Basel, Switzerland. As reported on 21 April 2020, followingtreatment with RUCONEST®,fever resolved in four of the five patients within 48 hours, and laboratory markers of inflammation decreased significantly (CRP, IL-6). Soon thereafter, four of the five patients were discharged from the hospital as fully recovered. One patient had increased oxygen requirement and was temporarily transferred to the ICU for intubation but over the subsequent days made a full recovery. Given this was a small case series, the outcomes were retrospectively compared to a matched control population of 15 patients. Baseline characteristics, admission laboratory parameters and treatments administered were similar in both groups. Both groups received standard of care as well as experimental therapies including antiviral and anti-cytokine directed medications. However, 8/15 (53%) patients in the control population required mechanical ventilation and 4 of these patients died, compared to only 1 (20%) requiring mechanical ventilation and no deaths in the RUCONEST® group. Overall, treatment with, in total five normal dose equivalents of RUCONEST® over 48h was well-tolerated. The full publication is available on the company’s website www.pharming.com

    Further important news:
    Pharming announces enrolment of first patient in multinational clinical trial for the treatment of COVID-19 with RUCONEST®

    Highlights:
    • Clinical trial follows encouraging results from five patients with confirmed COVID-19 infections administered RUCONEST® to treat the related severe pneumonia
    • First patient at the University Hospital Basel, Basel, Switzerland, with confirmed COVID-19 infection has been enrolled in a clinical trial to investigate the use of RUCONEST® to prevent severe SARS-CoV-2 infection in hospitalised patients with COVID-19
    • Study to be extended to additional clinical centres in Switzerland, Mexico and Brazil
    • Additional study in multiple centres in the US in final stages of preparation
    https://www.prnewswire.co.uk/news-r...t-of-covid-19-with-ruconest-r--826834736.html
     
  2. Vincent Gruszkiewicz

    Joined:
    Sep 3, 2020
    Messages:
    2
    Likes Received:
    0
    Kontrol Energy is a company that is in the final stage of making a device that will be able to monitor the existence of covid-19 virus present in the air, which will be beneficial in schools, classrooms, and anywhere there is a meeting.

    Kontrol Energy is making a product that will be able to sense the covid-19 and other types of viruses that are present in indoor
    spaces, which will be useful in schools and meetings.
     
    #22 Vincent Gruszkiewicz, Sep 4, 2020
    Last edited by a moderator: Sep 4, 2020

Share This Page